熱門資訊> 正文
Dianthus Therapeutics报告FY结果
2024-03-22 05:16
- Dianthus Therapeutics press release (NASDAQ:DNTH): Net loss for the year ended December 31, 2023 was $43.6 million or $8.45 net loss per share (basic and diluted) compared to $28.5 million or $32.57 net loss for the year ended December 31, 2022.
- Research and development (R&D) expenses for the year ended December 31, 2023 were $32.8 million, inclusive of $0.9 million of stock-based compensation, compared to $29.4 million for the year ended December 31, 2022, which included $0.4 million of stock-based compensation.
- $389 million of pro forma cash includes cash, cash equivalents and short-term investments as of December 31, 2023
More on Dianthus Therapeutics
- Stifel starts Dianthus at buy, cites market potential of lead drug
- Historical earnings data for Magenta Therapeutics
- Financial information for Magenta Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
